INTRODUCTION:

The human eye is one of the most sensitive and complex organs in the body. It comprises multiple layers and structures such as the cornea, conjunctiva, sclera, aqueous humor, vitreous humor, and retina.¹ Due to this complexity, developing an efficient ocular drug delivery system poses a significant challenge for pharmaceutical scientists. Conventional ocular dosage forms like eye drops and ointments exhibit poor bioavailability because of precorneal factors like lacrimation, tear turnover, and nasolacrimal drainage.² This result in less than 5% of the administered dose reaching intraocular tissues.

Hence, the need for advanced ocular drug delivery systems that enhance drug retention time and permeability has become crucial. Ocular diseases such as glaucoma, conjunctivitis, dry eye syndrome, and age-related macular degeneration have prompted extensive research into novel delivery systems.

Ocular Anatomy and Drug Delivery Challenges:

The human eye is a highly specialized and sensitive organ responsible for vision. It converts light stimuli into electrical signals that are interpreted by the brain. Owing to its intricate anatomy and multiple protective barriers, ocular drug delivery remains one of the most challenging areas in pharmaceutical research. The ocular surface and inner structures are designed to protect the eye from environmental exposure and pathogens, but these same defense mechanisms also limit drug penetration.³

Anatomy of the Eye Related to Drug Delivery:

The eye is composed of two major segments:

1. Anterior Segment: Includes the cornea, conjunctiva, aqueous humor, iris, lens, and ciliary body. Most topical ophthalmic formulations such as eye drops and ointments are designed to act on this region. Diseases affecting this part include conjunctivitis, dry eye syndrome, and glaucoma.

2. Posterior Segment: Includes the vitreous humor, retina, choroid, and optic nerve. Delivering drugs to this region is extremely difficult due to blood-retinal barriers. Common disorders include age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa.⁴

Figure 1. Anatomy of the Human Eye Relevant to Drug Delivery

The structure of the human eye is shown in Figure 1, highlighting key regions important for ocular drug delivery:

1. Cornea: Transparent surface that acts as the main barrier to drug penetration.

2. Conjunctiva: Mucous membrane covering the sclera; provides alternative absorption pathway.

3. Sclera: Dense connective tissue protecting the eye.

4. Aqueous Humor: Fluid: filled anterior chamber that facilitates drug transport.

5. Lens: Focuses light onto the retina and is impermeable to many drugs.

6. Vitreous Humor: Gellike mass acting as a diffusion barrier.

7. Retina and Choroid: Primary targets for posterior drug delivery.

8. Optic Nerve: Carries visual signals to the brain.⁵

Routes of Ocular Drug Delivery:

1. Intracameral Route:

Drug is administered into the anterior or posterior chambers of the eye, often during surgery.

2. Intravitreal Route:

Drug is injected into the vitreous humor for treating posterior segment diseases such as retinal disorders.

3. Topical Route:

Involves eye drops, ointments, gels, and emulsions applied on the eye surface; convenient and non-invasive.

4. Periocular Route:

Involves administration of drugs around the eye, mainly corticosteroids for inflammation.

5. Suprachoroidal Route:

Targets the space between the sclera and choroid for posterior segment delivery.

6. Subconjunctival Route:

Drug is injected under the conjunctiva to bypass corneal barriers.

7. Systemic Route:

Drug reaches the ocular tissues via systemic circulation, though limited by the blood-ocular barrier.

8. Retrobulbar Route:

Drug is injected into the retrobulbar space, typically for anesthesia or severe infections.⁶

Figure 2: Routes of Occular drug delivery System

Barriers Affecting Ocular Drug Delivery:

The effectiveness of ocular drug therapy is restricted by several physiological barriers:

1. Precorneal barriers:

Tear film, blinking, and nasolacrimal drainage rapidly eliminate drugs from the ocular surface.

2. Corneal barrier:

The corneal epithelium is lipophilic and resists the entry of hydrophilic drugs.

3. Conjunctival and scleral barriers:

Allow only limited paracellular transport.⁷

4. Blood-ocular barriers:

Include the blood-aqueous and blood-retinal barriers, which restrict systemic drug entry into ocular tissues.

5. Efflux transporters:

P-glycoproteins and other efflux pumps reduce intraocular drug accumulation.⁸

Figure 3 :Barriers in Occular drug delivery System

Need for Advanced Ocular Drug Delivery Systems

To overcome these barriers, researchers have developed advanced ocular drug delivery systems that prolong drug contact time and enhance corneal penetration. Examples include:

1. In-situ gels that transform from liquid to gel upon contact with tear fluid.

2. Nanoparticles and liposomes that improve penetration through corneal layers.

3. Ocular inserts and implants that provide sustained release.⁹

4. Microneedles and iontophoretic systems that enable targeted posterior segment delivery.

The ultimate goal is to achieve controlled, sustained, and site-specific drug release while maintaining patient comfort and compliance.¹⁰

Ocular Dosage Forms:

Ocular drug delivery systems can be classified as liquid, semi-solid, solid, and advanced (novel) systems.

1. Eye Drops:

Sterile liquid preparations applied to the eye surface for treating infections, dryness, allergies, or inflammation with rapid effect.¹¹

2. Eye Ointments:

Semi-solid greasy preparations providing prolonged contact time with ocular tissues, ideal for infections and post-surgical care.

3. Eye Gels:

Viscous semi-solid systems enhancing retention time and drug absorption, used for sustained release and better patient compliance.¹²

4. Eye Suspensions:

Dispersion of finely divided drug particles in a liquid medium for insoluble drugs, offering prolonged therapeutic action.

5. Eye Emulsions:

Heterogeneous systems of oil and water phases improving solubility and stability of lipophilic drugs for ocular use.

6. In-Situ Gels:

Liquid formulations that transform into gels upon contact with ocular fluids, enhancing retention and controlled drug release.

7. Ocular Inserts:

Solid or semi-solid sterile devices placed in the cul-de-sac for controlled and sustained drug release over long periods.

8. Eye Powders:

Dry formulations reconstituted with sterile diluent before use; used for heat-sensitive drugs requiring precise dosage control.¹³

9. Nanoparticle Suspensions:

Colloidal carriers like liposomes or polymeric nanoparticles improving ocular bioavailability and reducing systemic drug absorption.

10. Therapeutic Contact Lenses:

Soft lenses impregnated with drugs providing continuous and sustained ocular delivery, enhancing patient comfort and compliance.¹⁴

Advantages of Ocular Drug Delivery Systems:

1. Allows sustained and controlled drug release, maintaining therapeutic concentration for extended durations.

2. Provides targeted local drug action directly at the site of infection or inflammation.

3. Improves patient compliance due to reduced dosing frequency and convenient administration.

4. Bypasses first-pass metabolism, enhancing drug efficacy.

5. Minimizes systemic side effects by localizing the drug effect to ocular tissues.

6. Enhances bioavailability with advanced formulations like gels, inserts, or nanoparticles.¹⁶

7. Enables rapid onset of action in emergency conditions such as glaucoma attacks.

8. Protects sensitive ocular tissues by using sterile and biocompatible excipients.

9. Allows self-administration by patients without professional assistance.¹⁷

Disadvantages of Ocular Drug Delivery Systems:

1. Poor bioavailability in conventional forms due to precorneal drug loss and tear drainage.

2. Risk of microbial contamination during storage or repeated use.

3. Difficult formulation development because of ocular barriers and sensitivity.

4. Stability issues arising from sterilization and preservative incompatibility.

5. Possible blurred vision immediately after application of viscous formulations or ointments.¹⁸

6. Local irritation or allergic reactions may occur with certain excipients or preservatives.

7. Limited drug absorption due to the small absorptive surface area of the cornea.¹⁹

Recent Advances in Ocular Drug Delivery:

Recent research has focused on developing innovative ocular delivery platforms such as:

1. Nanoparticles and liposomes: Enhance drug stability and penetration.

2. In-situ gels: Undergo sol-to-gel transformation upon contact with tear fluid, prolonging residence time.

3. Ocular inserts: Provide controlled drug release without frequent dosing.²⁰

4. Microneedles and implants: Allow precise delivery to the posterior segment of the eye.²¹

CONCLUSION:

The ocular drug delivery system remains a critical area of pharmaceutical research due to the eye’s complex anatomy and unique physiological barriers that limit drug absorption. Traditional formulations such as eye drops and ointments offer limited bioavailability, prompting the development of advanced and targeted drug delivery technologies. Innovations such as in-situ gels, nanoparticles, liposomes, and ocular inserts have significantly improved drug retention, permeability, and therapeutic outcomes. These novel systems not only enhance patient compliance but also ensure sustained and controlled release, reducing the frequency of administration and systemic side effects.

Future research should focus on optimizing biocompatible polymers, exploring non-invasive delivery routes, and integrating nanotechnology with smart responsive systems to achieve site-specific, long-acting, and patient-friendly ocular therapies. With continued advancements in formulation science and biomedical engineering, the next generation of ocular drug delivery systems holds great promise for the effective management of both anterior and posterior segment eye diseases.

REFERENCES:

1. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol. 2013; 2(2): 47–64.

2. Singh M, Tyagi S, Verma R. Recent advances in ocular drug delivery systems. Res J Pharmacodyn Pharmacol. 2020; 12(1):33–42.

3. Nanjwade BK, et al. Development and evaluation of in-situ gelling systems for ocular drug delivery. Res J Pharmacodyn Pharmacol. 2019; 11(3): 127–134.

4. Kumar S, et al. Nanotechnology in ophthalmic drug delivery. Res J Pharmacodyn Pharmacol. 2021; 13(2): 55–63.

5. Jain R, et al. Ocular barriers and strategies to overcome them. Int J Pharm Sci Res. 2018; 9(4): 1345–1353.

6. Shinde GS, Rao PS, Jadhav RS, Kolhe P, Athare D. A review on chromatography and advancement in paper chromatography technique. Asian Journal of Pharmaceutical Analysis. 2021; 11(1): 45-8

7. Chauhan A, Radke CJ. Controlled release of drugs from ophthalmic delivery systems. Adv Drug Deliv Rev. 2012; 64(6): 666–685.

8. Shinde, G. S., Jadhav, R., Vikhe, D., and Kote, R. B. Development and evaluation of herbal fast disintegrating tablet of Achyranthes aspera linn root extract. Asian Journal of Pharmacy and Technology, 2024: 14(2): 119-122.

9. Shinde, G. S, Jadhav R S, Tambe V B, Kote R B .RP-HPLC Method Development and Validation of Lamivudine, Zidovudine and Nevirapine in Bulk and Dosage form using UV Detector." Research Journal of Pharmacy and Technology. 2024; 17(10): 5011-5015

10. Suresh PK, Barsa G, Sah AK, Daharwal SJ. Ocular implants as drug delivery device in ophthalmic therapeutics: An overview. Res J Pharm Technol. 2014; 7(6): 687–693.

11. Shinde GS, Jadhav RS, Kote RB, Kadam AJ, Bankar AA. Bioanalytical Method Development and Validation of UV Spectrophotometric Method for Estimation of Metformin Hydrochloride in Urine Sample. Asian J Res Chem. 2024; 17(2): 93–6. doi: 10.52711/0974-4150.2024.00019

12. Karthikeyan D, Vijaikumar S, Pandey VP, Nandha Kumar J, Sengottuvelu S, Shivakumar T. Preparation and evaluation of ocular inserts for controlled delivery of Ciprofloxacin hydrochloride. Res J Pharm Technol. 2008; 1(1): 37–41.

13. Nautiyal D, Singh V, Ali S. Formulation and evaluation of sustained release of Ofloxacin ocular inserts. Res J Pharm Technol. 2012; 5(12): 1533–1538.

14. Karthikeyan D, Sonkar S, Pandey VP, Nandha Kumar J, Sengottuvelu S, Bhowmick M, Shivakumar T. Development and characterization of modified ocular inserts with improved ocular compatibility. Res J Pharm Technol. 2008; 1(2): 93–99.

15. Godge RK, Shinde GS, Joshi S. Simultaneous Estimation and Validation of Dapagliflozin and Saxagliptin in Bulk Drug and Dosage Form by RP-HPLC. Research Journal of Science and Technology. 2019; 11(1):59-63

16. Gupta SK, Singhvi IL. In-situ gelling system and other possible innovative approach for ocular disease: A review. Res J Pharm Technol. 2011; 4(6): 825–829.

17. Shinde V, Amsa P, Tamizharasi S, Karthikeyan D, Shivakumar T, Kale A. Formulation and characterization of Eudragit RS 100 nanosuspension for ocular delivery of indomethacin. Res J Pharm Technol. 2010;3(3):779–784.

18. Nayak S, Jadhav M, Bhaskar V. Recent advances in ocular drug delivery system. Res J Pharm Technol. 2016; 9(7): 789–795.

19. Shinde G, Godage RK, Jadhav RS, Manoj B, Aniket B. A Review on Advances in UV Spectroscopy. Research Journal of Science and Technology. 2020; 12(1): 47-51.

20. Nair RV, Nair SC, Anoop KR. Current trends in ocular drug systems and its applications. Res J Pharm Technol. 2015; 8(5): 589–595.

21. Pawar P, Yadav A, Gharge V. Ocular drug delivery and novel formulation: A review. Asian J Pharm Technol. 2018; 8(4): 218–224

Received on 10.11.2025 Revised on 06.12.2025

Accepted on 24.12.2025 Published on 12.02.2026

Available online from February 14, 2026

Res.J. Pharmacology and Pharmacodynamics.2026;18(1):107-110.

DOI: 10.52711/2321-5836.2026.00014

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.

A Review on Ocular Drug Delivery System